Lineage Cell Therapeutics LCTX
NYSE LCTX
$1.00 +0.02 (+2.03%)
As of: Oct 23, 2026 · 2:10 PM EDT

Lineage Cell Therapeutics (LCTX) Return on Sales [ROS] (2010 - 2026)

Updated

Lineage Cell Therapeutics (LCTX) reported Return on Sales [ROS] of -834.71% for Q2 2026, down 119.33 percentage points from -715.37% a year earlier and down 394.53 percentage points from the prior quarter.

Analysis

Lineage Cell Therapeutics (LCTX) Return on Sales [ROS] (2010 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Lineage Cell Therapeutics' Return on Sales [ROS] came in at -205.23%, up 117.61 percentage points year-over-year; for FY2025, it was -251.57%, down 25.47 percentage points from FY2024.

  • Return on Sales [ROS] has a five-year change of +1196.78 percentage points (FY2020 to FY2025).
  • By year, Return on Sales [ROS] came in at -226.11% in FY2024 (+50.39 pp), -276.50% in FY2023 (-123.33 pp), -153.17% in FY2022 (+980.47 pp) and -1133.63% in FY2021 (+314.72 pp).
  • The Q2 2026 figure ranks as the lowest quarterly Return on Sales [ROS] since Q4 2021.
  • Year over year, Return on Sales [ROS] gained in four of the last eight quarters, with an average year-over-year change of +30.50 percentage points.
  • The high point for year-over-year Return on Sales [ROS] in five years was Q4 2022 (a gain of 2070.95 percentage points); the low point was Q4 2021 (a drop of 760.74 percentage points).
  • Per Business Quant data, the three quarters before Q2 2026 came in at -440.17% (Q1 2026), -99.09% (Q4 2025) and -102.85% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,126.20 Bn 1,094.78 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 633.36 Bn 553.22 Bn 17.30 Bn 24.35%
3 AbbVie 504.51 Bn 477.62 Bn 12.70 Bn 37.86%
4 Merck 357.58 Bn 311.96 Bn 12.21 Bn -3.52%
5 Novartis Ag 289.65 Bn 253.64 Bn 11.24 Bn 32.97%
6 Astrazeneca 264.97 Bn 238.66 Bn 12.86 Bn 20.57%
7 Amgen 237.69 Bn 193.09 Bn 7.24 Bn 34.95%
8 Gilead Sciences 194.48 Bn 168.68 Bn 6.22 Bn -133.21%
9 Pfizer 171.00 Bn 117.64 Bn 10.94 Bn 28.37%
10 Lineage Cell Therapeutics 250.75 Mn 50.27 Mn - -834.71%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -834.71%
Mar 31, 2026 -440.17%
Dec 31, 2025 -99.09%
Sep 30, 2025 -102.85%
Jun 30, 2025 -715.37%
Mar 31, 2025 -433.09%
Dec 31, 2024 -178.17%
Sep 30, 2024 -101.61%
Jun 30, 2024 -416.69%
Mar 31, 2024 -461.29%
Dec 31, 2023 -304.69%
Sep 30, 2023 -538.12%
Jun 30, 2023 -155.78%
Mar 31, 2023 -278.37%
Dec 31, 2022 -346.68%
Sep 30, 2022 -175.15%
Jun 30, 2022 -92.99%
Mar 31, 2022 -122.13%
Dec 31, 2021 -2,417.64%
Sep 30, 2021 -301.45%
API Access

Lineage Cell Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=LCTX&period=max&api_key=YOUR_API_KEY